DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on April 23, 2009; DOI: 10.1124/dmd.109.026674


0090-9556/09/3707-1548-1556$20.00
DMD 37:1548-1556, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.109.026674v1
37/7/1548    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Liu, X.
Right arrow Articles by Weikert, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, X.
Right arrow Articles by Weikert, R.

Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in Rats

Xingrong Liu1, Olga Vilenski, Joyce Kwan, Subbu Apparsundaram, and Robert Weikert

Roche Palo Alto, LLC, Palo Alto, California

It is a commonly accepted hypothesis that central nervous system (CNS) activity is determined by the unbound brain drug concentration. However, limited experimental data are available in the literature to support this hypothesis. The objective of this study was to test this hypothesis by examining the relationship between in vitro binding affinity (KI) and in vivo activity quantified as the drug concentration occupying 50% of the transporters (OC50) for 18 serotonin (SERT) and dopamine transporter (DAT) inhibitors. In vivo rat OC50 was determined by autoradiography using [3H]N,N-dimethyl-2,2-amino-4-cyanophenylthiobenzylamine and [3H](–)-2-β-carbomethoxy-3-β-(4-fluorophenyl)tropane-1,5-napthalenedisulfonate (WIN35,428) as the ligands to assess SERT and DAT occupancy, respectively. The unbound brain concentrations were calculated from total brain concentrations and the unbound brain fraction, which was determined by the brain homogenate method. The in vivo total brain SERT and DAT OC50 values (mean ± S.D.) were 408 ± 368- and 410 ± 395-fold greater than the KI values, respectively. In contrast, the in vivo unbound brain SERT and DAT OC50 values were only 3.3 ± 2.1- and 4.1 ± 4.0-fold different from the KI values. Therefore, prediction of the biophase drug concentration by using the unbound brain concentration rather than the total brain concentration results in an approximately 100-fold improvement for the accuracy. In the present study, a 10-fold improvement was also observed by using the unbound plasma concentration rather than the total plasma concentration to predict the biophase concentration in the brain. This study supports the hypothesis that CNS activity is more accurately determined by the unbound brain drug concentration and not by the total brain drug concentration.


Address correspondence to: Dr. Xingrong Liu, Genentech, Inc., MS: 41-2A, 1 DNA Way, South San Francisco, CA 94080. E-mail: liu.xingrong{at}gene.com







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.